MA55140A - Méthode sûre et efficace de traitement de la rectocolite hémorragique avec un anticorps anti-il12/il23 - Google Patents

Méthode sûre et efficace de traitement de la rectocolite hémorragique avec un anticorps anti-il12/il23

Info

Publication number
MA55140A
MA55140A MA055140A MA55140A MA55140A MA 55140 A MA55140 A MA 55140A MA 055140 A MA055140 A MA 055140A MA 55140 A MA55140 A MA 55140A MA 55140 A MA55140 A MA 55140A
Authority
MA
Morocco
Prior art keywords
ultracolitis
antibody
safe
treating
effective method
Prior art date
Application number
MA055140A
Other languages
English (en)
Other versions
MA55140B1 (fr
Inventor
Omoniyi Adedokun
Jewel Johanns
Katherine Li
Colleen Marano
Christopher O'brien
Kimberly Shields-Tuttle
Richard Strauss
Hongyan Zhang
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Priority claimed from PCT/IB2019/058098 external-priority patent/WO2020065532A1/fr
Publication of MA55140A publication Critical patent/MA55140A/fr
Publication of MA55140B1 publication Critical patent/MA55140B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA55140A 2018-09-24 2019-09-24 Méthode sûre et efficace de traitement de la rectocolite hémorragique avec un anticorps anti-il12/il23 MA55140B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862735501P 2018-09-24 2018-09-24
PCT/IB2019/058098 WO2020065532A1 (fr) 2018-09-24 2019-09-24 Méthode sûre et efficace de traitement de la rectocolite hémorragique avec un anticorps anti-il12/il23

Publications (2)

Publication Number Publication Date
MA55140A true MA55140A (fr) 2021-09-29
MA55140B1 MA55140B1 (fr) 2023-09-27

Family

ID=88507038

Family Applications (1)

Application Number Title Priority Date Filing Date
MA55140A MA55140B1 (fr) 2018-09-24 2019-09-24 Méthode sûre et efficace de traitement de la rectocolite hémorragique avec un anticorps anti-il12/il23

Country Status (1)

Country Link
MA (1) MA55140B1 (fr)

Also Published As

Publication number Publication date
MA55140B1 (fr) 2023-09-27

Similar Documents

Publication Publication Date Title
EP3883606A4 (fr) Méthode sûre et efficace de traitement de la rectocolite hémorragique avec un anticorps anti-il12/il23
MA50666A (fr) Méthode sûre et efficace de traitement de lupus avec un anticorps anti-il12/il23
EP2975055A4 (fr) Anticorps anti-c5 et méthode de prévention et de traitement de maladies liées au complément
MA71708A (fr) Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1
EP3706794A4 (fr) Méthode sûre et efficace de traitement de l'arthrite psoriasique par un anticorps spécifique anti-il23
HRP20260008T1 (hr) Sigurna i učinkovita metoda liječenja psorijaze pomoću protutijela specifičnog za il23
MA44510A (fr) Methode de traitement du psoriasis avec dosage intervalle augmenté d'anticorps anti-il12 et/ou -23
EP3838289A4 (fr) Anticorps anti-tigit et ses utilisations
EP3589660A4 (fr) Anticorps anti-pd-l1 et utilisations associées
EP3897722A4 (fr) Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23
EP3395353A4 (fr) Méthode de prévention ou de traitement de la neuropathie diabétique et des affections associées
EP3427678A4 (fr) Dispositif médical et méthode de traitement
EP3920693A4 (fr) Anticorps anti-nme et méthode de traitement du cancer ou de métastases cancéreuses
EP3877037A4 (fr) Méthode et système de traitement de neurorégénération
EP3503903A4 (fr) Traitement ascaroside de maladies auto-immunes et inflammatoires
EP3683580A4 (fr) Stylo de détection électronique et méthode de détection précoce du nombre de semaines de grossesse
EP3778649A4 (fr) Méthode et composition de traitement de tumeurs
FR3026745B1 (fr) Methode d'analyse et interpretation automatisee d'un antibiogramme
LT4200018T (lt) Anti-par-2 antikūnai ir jų panaudojimo būdas
EP3465349A4 (fr) Procédé amélioré de modélisation et de simulation par ordinateur de photorésines à développement de ton négatif
EP3564826A4 (fr) Procédé de traitement de fichier et serveur
IL283136A (en) Antibodies to mucin-16 and methods of use thereof
MA43717A (fr) Anticorps anti-tnf et fragments fonctionnels de ceux-ci
EP3883607A4 (fr) Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
MA56124A (fr) Méthode sûre et efficace de traitement de l'arthrite psoriasique au moyen d'un anticorps spécifique anti-il23